Results from the Phase 3 PEACHTREE Clinical Trial: Systemic Therapy and the Efficacy of CLS-TA, a Post-Hoc Analysis

Retina Society 2020 Virtual Program
Pauline T. Merrill, MD
Thomas A. Ciulla, MD, MBA

1. Rush University and Illinois Retina Associates, IL, USA
2. Clearside Biomedical, Inc. GA, USA
Financial Disclosures

• PTM:
  – Study funding: Clearside, Gilead, Santen, NEI
  – Consulting: Santen, Eyepoint, Alimera

• TAC:
  – Employment & Financial Interest: Clearside Biomedical
Key Takeaways

• The benefit of suprachoroidally injected CLS-TA versus the control in treating macular edema associated with non-infectious uveitis was noted regardless of administration of systemic therapy at baseline

• These results corroborate the prespecified study analyses in PEACHTREE
Core Advantages of Treating Via the Suprachoroidal Space

**TARGETED**
The back of the eye is the location of many irreversible and debilitating visual impairments\(^1\)

**COMPARTMENTALIZED**
Drug is compartmentalized in the suprachoroidal space, which helps keep it away from non-diseased tissues\(^2\)

**BIOAVAILABLE**
Fluid spreads circumferentially and posteriorly when injected within the suprachoroidal space, bathing the choroid and adjacent areas with drug\(^3\)

PK = pharmacokinetic

Sources:
Background: Suprachoroidal Delivery of Corticosteroids

• PEACHTREE: Macular Edema in NIU met Primary Endpoint
  - 46.9% of subjects gained ≥15 BCVA letters from baseline vs. 15.6% in the control

Mean change from baseline in BCVA by visit

- Treatment of uveitis often requires a combination of systemic and local therapies
- This analysis explores the efficacy in patients receiving and not receiving other systemic therapies at baseline.
Safety: PEACTHREE

<table>
<thead>
<tr>
<th>IOP-Related Events</th>
<th>CLS-TA 4.0 mg N = 96</th>
<th>Control N = 64</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated IOP adverse events</td>
<td>11 (11.5%)</td>
<td>10 (15.6%)</td>
</tr>
<tr>
<td>IOP elevation ≥10 mmHg change from baseline at any visit*</td>
<td>9 (9.4%)</td>
<td>7 (10.9%)</td>
</tr>
<tr>
<td>IOP elevation ≥30 mmHg absolute reading at any post baseline visit*</td>
<td>5 (5.2%)</td>
<td>4 (6.3%)</td>
</tr>
<tr>
<td>Given any additional IOP-lowering medication</td>
<td>7 (7.3%)</td>
<td>6 (9.4%)</td>
</tr>
<tr>
<td>Any surgical intervention for an elevated IOP Adverse Event</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

- Cataract: 7.3% (7/96) in the CLS-TA arm vs. 6.3% (4/64) in the sham arm
- One serious ocular AE
  - Retinal detachment 8 weeks after CLS-TA
  - Determined to be unrelated to study drug by the Investigator
Post Hoc Analysis: Objectives and Methods

- In PEACHTREE, enrollment criteria allowed for:
  - low dose corticosteroid or
  - stable dose of immunomodulatory therapy throughout study if no increase anticipated during study
- Post-hoc analyses were performed to evaluate improvement in BCVA and CST in subjects receiving systemic corticosteroids and/or steroid-sparing therapy at baseline versus subjects receiving no systemic therapies
  - Dosage reduction / stoppage during study after baseline not accounted for in analysis
### Results

<table>
<thead>
<tr>
<th>Any Systemic Steroid or Steroid-Sparing Therapy at Baseline</th>
<th>CLS-TA n=96</th>
<th>Control n=64</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NO Systemic Therapy</strong></td>
<td>68/96 (70.8%)</td>
<td>49/64 (76.6%)</td>
</tr>
<tr>
<td><strong>YES Systemic Therapy</strong> (steroid and/or steroid-sparing)</td>
<td>28/96 (29.2%)</td>
<td>15/64 (23.4%)</td>
</tr>
</tbody>
</table>
Mean change in BCVA significantly greater than control in both CLS-TA groups

**CLS-TA + No Systemic Therapy:**
At Week 24: Change in BCVA +15.6 letters versus +4.9 in the control (p < 0.001)

**CLS-TA + Systemic Therapy**
At Week 24: Change in BCVA was +9.4 letters versus -3.2 in the control (p = 0.019)

Intention-to-treat population; LOCF imputation.
Mean change in CST significantly greater than control in No Systemic Therapy group

CLS-TA + Systemic Therapy
At Week 24: Reduction in CST was 108.3 µm versus 43.5 µm in the control (p = 0.19)

CLS-TA + No Systemic Therapy
At Week 24: Reduction in CST was 169.8 µm vs. 10.3 µm in the control (p < 0.001)

Intention-to-treat population; LOCF imputation.
Conclusion

• The benefit of suprachoroidally injected CLS-TA versus the control in treating macular edema associated with non-infectious uveitis was noted regardless of administration of systemic therapy at baseline

• These results corroborate the prespecified study analyses in PEACHTREE